TAGLN2 has also been shown to be dysregulated in multiple cancer types, such as colorectal [15, 17, 18], breast [19, 20], cervical [21], lung [22, 23], hepatocellular [24, 25], pancreatic [26, 27], head and neck [28], meningiomas [29] and more recently gliomas [30]. Here, TAGLN2 is linked to glioma.